C4 Therapeutics, Inc.
CCCC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $59 | $78 | $51 | $55 |
| Short-Term Investments | $133 | $136 | $164 | $189 |
| Receivables | $7 | $2 | $8 | $3 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $8 | $8 | $9 | $10 |
| Total Curr. Assets | $207 | $225 | $233 | $258 |
| Property Plant & Equip (Net) | $47 | $60 | $61 | $63 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $8 | $12 | $20 | $22 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $4 | $0 | $6 | $6 |
| Total NC Assets | $59 | $72 | $87 | $92 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $265 | $297 | $320 | $350 |
| Liabilities | – | – | – | – |
| Payables | $1 | $2 | $1 | $1 |
| Short-Term Debt | $6 | $6 | $6 | $6 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $17 | $23 | $22 | $19 |
| Other Curr. Liab. | $11 | $14 | $13 | $19 |
| Total Curr. Liab. | $36 | $44 | $41 | $45 |
| LT Debt | $55 | $57 | $58 | $60 |
| Deferred Rev, NC | $20 | $21 | $25 | $28 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $75 | $78 | $84 | $88 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $61 | $63 | $64 | $66 |
| Total Liabilities | $111 | $122 | $124 | $134 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$718 | -$686 | -$660 | -$634 |
| AOCI | $0 | -$0 | $0 | $0 |
| Other Equity | $873 | $860 | $855 | $850 |
| Total Equity | $154 | $174 | $195 | $216 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $265 | $297 | $320 | $350 |
| Net Debt | $3 | -$15 | $13 | $10 |